Skip to main content
. Author manuscript; available in PMC: 2019 Apr 1.
Published in final edited form as: Gastroenterology. 2017 Dec 24;154(5):1449–1464.e20. doi: 10.1053/j.gastro.2017.12.019

Figure 5. NR1D1 pharmacological activation inhibits the NLRP3 inflammasome pathway in primary macrophages.

Figure 5

(A) Nlrp3 mRNA levels in LPS-primed (LPS) or not (NT) BMDMs treated with SR9009 (n=3). (B) NLRP3 protein levels in LPS-primed (LPS) or not (/) BMDMs treated with SR9009 or DMSO (representative of 3 independent experiments). (C) NLRP3 and (E) IL1β mRNA levels in LPS-primed human MDMs pre-treated with SR9009 or not (Vehicle) (n=3). (D) Il1β and (F) Il18 mRNA levels in LPS-primed BMDMs pre-treated or not with SR9009 (n=3). (G) pro- and matured IL1B protein expression in LPS-primed BMDM or not (NT) and treated with SR9009 or not (Vhc). (H) IL1B secretion in LPS-primed and ATP-activated BMDMs pre-treated with SR9009 or not (Vehicle) (n=3) (I) IL1B and (J) IL18 secretion in LPS-primed and ATP-activated human MDMs pre-treated with SR9009 or not (Vehicle) (n=3). Data are represented as means ± SD. °°°p<0.001 in LPS vs unstimulated vehicle condition (A); *p<0.05, **p<0.01, ***p<0.001 as determined by one-way ANOVA (A) or two-way ANOVA (C–F, H–J) followed by a Bonferroni post-hoc test.